Long Term Efficacy and Safety of Laronidase for MPS I episode artwork

EPISODE · Aug 4, 2009 · 14 MIN

Long Term Efficacy and Safety of Laronidase for MPS I

from Clinician's Roundtable

Host: Bruce Bloom, DDS, JD Guest: Emil Kakkis, MD, PhD Host Dr. Bruce Bloom welcomes Dr. Emil Kakkis, an advisor at BioMarin Pharmaceutical Inc. and author of numerous published articles on mucopolysaccharidosis I, or MPS I, to discuss current treatment options. They discuss the benefits and risks of enzyme replacement therapy with laronidase. Don't miss these other programs on MPS I, with host Dr. Bruce Bloom: Challenges in Management of MPS I Immune System Irregularities in Lysosomal Storage Disorders Musculoskeletal Aspects of MPS I: Diagnosis and Management Considerations

Episode metadata supplied by the publisher feed · Published Aug 4, 2009

Embed this episode

NOW PLAYING

Long Term Efficacy and Safety of Laronidase for MPS I

0:00 14:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Clinician's Roundtable?

This episode is 14 minutes long.

When was this Clinician's Roundtable episode published?

This episode was published on August 4, 2009.

Can I download this Clinician's Roundtable episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!